Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RenovoRx (RNXT) Research & Development (2024 - 2025)

RenovoRx (RNXT) has disclosed Research & Development for 2 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 4.76% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, up 3.8% year-over-year, with the annual reading at $6.3 million for FY2025, 4.05% up from the prior year.
  • Research & Development hit $1.5 million in Q4 2025 for RenovoRx, down from $1.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.7 million in Q3 2025 to a low of $1.3 million in Q1 2024.